The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies. 

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market has experienced robust growth, escalating from $5.24 billion in 2023 to an estimated $5.69 billion in 2024. This surge reflects a commendable Compound Annual Growth Rate (CAGR) of 8.7%. The growth in the historic period is attributed to an increased prevalence of underlying conditions, advancements in diagnostic tools, pharmaceutical developments, and the rise in global healthcare access.

Future Growth Prospects
Anticipating sustained growth, the market is poised to reach $7.67 billion in 2028, driven by a robust CAGR of 7.7%. The growth in the forecast period can be linked to the integration of telemedicine and remote monitoring, leveraging data analytics and artificial intelligence (AI), fostering patient education and support, and regulatory changes with evolving reimbursement policies. Major trends in the forecast period include the adoption of personalized treatment approaches, development of novel therapies, minimally invasive diagnostics, and the emergence of collaborative care models.

Diabetes Paves the Way
The escalating prevalence of diabetes is anticipated to be a key driver propelling the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. With diabetes affecting millions globally, EPI therapy, involving pancreatic enzyme replacement therapy (PERT), becomes crucial in improving nutrient absorption and glycemic control. In 2021, approximately 537 million adults were living with diabetes, projected to rise to 643 million by 2030 and 783 million by 2045. This surge underscores the growing need for effective EPI therapeutics and diagnostics.

Industry Leaders
Major players shaping the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market include Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, and other distinguished pharmaceutical entities. These industry leaders play a pivotal role in advancing treatment options and fortifying the market landscape.

View More On The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report 2023 – https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Driving Innovation in Studies and Solutions
Companies in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are steering their focus towards innovative studies and solutions. One noteworthy initiative is the launch of the PACT-CP study by Aimmune Therapeutics in June 2021. This patient-centric chronic pancreatitis registry study aims to comprehend unmet needs and therapeutic burdens on EPI patients due to chronic pancreatitis. By incorporating real-world data from about 400 patients across 20 gastroenterology facilities, this study brings a patient-driven approach to research.

Strategic Acquisitions Reshape the Landscape
In September 2021, AzurRx BioPharma strategically acquired First Wave Bio Inc. for $229 million, leading to AzurRx’s transformation into ‘First Wave BioPharma Inc.’ This acquisition significantly expands AzurRx’s gastrointestinal (GI) development pipeline, positioning the company for growth in the therapeutic area for inflammatory bowel illness. First Wave Bio Inc., specializing in treating EPI in patients with cystic fibrosis and chronic pancreatitis, contributes to the diversification of AzurRx’s portfolio.

Market Segmentation and Geographic Dominance
The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market encompasses diverse segments, including therapies, diagnostics, drug types, distribution channels, and end-users. Notably, North America emerged as the largest region in the market in 2023, emphasizing the region’s dominance in the industry.

Request A Sample Of The Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=12992&type=smp

The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Global Market Report 2023  provides a comprehensive overview on the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market size, trends and drivers, opportunities, strategies, and companies analysis. Through our reports businesses can effectively analyze data and frame well-informed strategies

View More Related Reports –
Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2023
Antacids Global Market Report 2023
Inflammatory Bowel Disease Treatment Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on: 
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model